MedPath

Factor IX Complex (Human)

Generic Name
Factor IX Complex (Human)
Brand Names
Profilnine
Drug Type
Biotech
CAS Number
37224-63-8
Unique Ingredient Identifier
FW411QXD5M

Overview

Factor IX Complex is a sterile, lyophilized concentrate composed of a number of Vitamin K-dependent clotting factors found in functioning human plasma. Also known as prothrombin complex concentrate, products containing this complex often include Factor IX (antihemophilic factor B), Factor II (prothrombin), Factor X (Stuart-Prower Factor), and low levels of Factor VII (proconvertin) derived from human plasma. Many commercially available products also contain low levels of other antithrombotic proteins. For example, Kcentra (FDA) also contains the antithrombotic proteins C and S, while Bebulin VH (FDA) contains heparin. Coagulation factors are purified from pooled human plasma and subsequently sterilized and treated. Although Factor IX Complex products contain many different coagulation components, Factor IX is the lead component for potency and efficacy, particularly when used for the treatment of bleeding associated with Hemophilia B (Factor IX deficiency). As the product Kcentra, Factor IX Complex is also indicated for the urgent reversal of acquired coagulation factor deficiency induced by Vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients experiencing acute major bleeding or requiring rapid reversal of therapy.

Indication

Factor IX Complex is indicated for the prevention and control of hemorrhagic episodes in hemophilia B patients. It is also indicated for the urgent reversal of acquired coagulation factor deficiency induced by Vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with acute major bleeding or who require rapid reversal of therapy.

Associated Conditions

  • Bleeding
  • Hemorrhage
  • Intracranial Hemorrhages

Clinical Trials

Title
Posted
Study ID
Phase
Status
Sponsor
2024/12/10
Phase 2
Recruiting
Institut de cancérologie Strasbourg Europe
2024/10/04
Not Applicable
Recruiting
Second Affiliated Hospital, School of Medicine, Zhejiang University
2023/11/22
Phase 4
Not yet recruiting
2022/12/29
Phase 4
Recruiting
2022/09/21
N/A
Completed
2021/12/14
Phase 3
Recruiting
2020/06/16
Phase 2
Terminated
IRCCS Policlinico S. Donato
2016/05/19
Phase 4
Completed
2015/12/04
Phase 3
Completed
2015/09/23
Phase 4
Completed

FDA Drug Approvals

Approved Product
Manufacturer
NDC Code
Route
Strength
Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product
Authorization Holder
Status
Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product
Manufacturer
Approval Number
Dosage Form
Strength
Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product
Company
Approval Number
Drug Type
Dosage Form
Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product
Registration No.
Company
Licence No.
Strength
Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product
ARTG ID
Sponsor
Registration Type
Status
Registration Date
No TGA approvals found for this drug.

Health Canada Drug Approvals

Approved Product
Company
DIN
Dosage Form
Strength
Market Date
BEBULIN VH INJ 1000UNIT/VIAL
osterreichisches institut fur haemoderivate ges m.b.h.
01992910
Powder For Solution - Intravenous
1000 UNIT / VIAL
12/31/1990
ALPHANINE PWS INJ 1500UNIT/VIAL
alpha therapeutic corporation
01924745
Powder For Solution - Intravenous
1500 UNIT / VIAL
12/31/1992
FEIBA VH IMMUNO ANTI INHIBITOR
osterreichisches institut fur haemoderivate ges m.b.h.
00609137
Powder For Solution - Intravenous
null NIL / ML
12/31/1986
BEBULIN VH 500UNIT/VIAL
osterreichisches institut fur haemoderivate ges m.b.h.
00781347
Powder - Intravenous
500 UNIT / 10 ML
12/31/1988

CIMA AEMPS Drug Approvals

Approved Product
Company
Registration Number
Pharmaceutical Form
Prescription Type
Status
No CIMA AEMPS (Spain) approvals found for this drug.

Philippines FDA Drug Approvals

Approved Product
Company
License Number
Dosage Form
Strength
Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

Approved Product
Company
License Number
Dosage Form
Strength
Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

Approved Product
Company
Registration Number
Dosage Form
Strength
Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

Medicine Name
MA Holder
MA Number
Pharmaceutical Form
Active Ingredient
Authorization Date
No UK EMC drug information found for this drug.

Help Us Improve

Your feedback helps us provide better drug information and insights.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.